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coronary artery disease
Wilbert S. Aronow
The review article by Athyros et al. [1] is an excellent review article.
Ic oncur with the issues discussed by the authors. This editorial discuss-
es my current approach to the management of patients with diabetes mel-
litus and coronary artery disease (CAD).
Patients with diabetes mellitus and CAD should be treated with opti-
mal medical management. All modifiable risk factors should be treated.
Patients should be strongly encouraged to stop smoking and be referred
to a smoking cessation program.
Hypertension should be treated with the blood pressure reduced to
< 140/90 mmHg [2]. The initial drug of choice should be an angiotensin-
converting enzyme (ACE) inhibitor [2].
The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Throm-
bolysis in Myocardial Infarction (PROVE IT-TIMI) 22 trial enrolled 4,162 patients
with an acute coronary syndrome (acute myocardial infarction with or with-
out ST-segment elevation or high-risk unstable angina pectoris) [3]. The low-
est cardiovascular events rates occurred with a systolic blood pressure
between 130 mmHg to 140 mmHg and a diastolic blood pressure between
80 mmHg to 90 mmHg with a nadir of 136/85 mmHg. An observational sub-
group analysis was performed in 6,400 of the 22, 576 persons enrolled in
the International Verapamil SR-Trandolapril Study (INVEST) who had dia-
betes and CAD [4]. Persons were categorized as having tight control of blood
pressure if they could maintain their systolic blood pressure below 130 mmHg
and their diastolic blood pressure below 85 mm Hg, usual control if they
could maintain their systolic blood pressure between 130 mmHg to
139 mmHg, and uncontrolled if their systolic blood pressure was 140 mmHg
or higher.
During 16,893 patient-years of follow-up, a cardiovascular event rate
of 12.6% occurred in patients with usual control of blood pressure vs. 19.8%
in patients with uncontrolled hypertension, p < 0.001. The incidence of
cardiovascular events was 12.6% in patients with usual control of blood
pressure vs. 12.7% in patients with tight control of blood pressure. The all-
cause mortality rate was 11.0% with tight control of blood pressure vs.
10.2% with usual control of blood pressure (p = 0.06). When extended fol-
low-up was included, the all-cause mortality rate was 22.8% with tight
control of blood pressure vs. 21.8% with usual control of blood pressure,
p = 0.04.
Dyslipidemia should be treated. The serum low-density lipoprotein cho-
lesterol should be reduced to < 70 mg/dl [5-7].
Diabetes mellitus should be treated with the hemoglobin A1c reduced
to < 7.0%. Hypoglycemia must be avoided in patients with CAD. In 10, 251
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high-risk diabetics in the Action to Control Cardio-
vascular Risk in Diabetes (ACCORD) Study, patients
randomized  to  intensive  treatment  reached
a hemoglobin A1c of 6.4%, and patients random-
ized to conventional treatment reached a hemo-
globin level of 7.5% [8]. At 3.5-year follow-up, inten-
sive therapy increased mortality 22% from 4.0% to
5.0% (p = 0.04) and did not significantly reduce
major cardiovascular events.
Obese diabetics with CAD must lose weight by
dietary therapy and by aerobic physical activity.
They should exercise for at least 30 min daily for 
7 days per week with a minimum of 5 days of phys-
ical exercise per week [9]. 
Diabetics with CAD should be treated with
aspirin, ACE inhibitors, ʲ-blockers, and statins to
reduce cardiovascular events and mortality and
coronary revascularization [6, 9-13]. Angina pectoris
should be treated with ʲ-blockers and nitrates [14].
If angina persists, I would add a calcium channel
blocker, and if needed, ranolazine.
In the Clinical Outcomes Utilizing Revascular-
ization and Aggressive Drug Evaluation (COURAGE)
trial, of 2, 248 patients with stable CAD randomized
to optimal medical therapy plus percutaneous coro-
nary intervention (PCI) vs. optimal medical therapy
alone, 766 patients (34%) had diabetes mellitus,
and 1,362 patients (61%) had the metabolic syn-
drome [15]. 
At 4.6-year median follow-up, the risk of death
or myocardial in infarction in patients with diabetes
mellitus and in patients with the metabolic syn-
drome was similar in patients with and without ear-
ly PCI. On the basis of these data, I would not rec-
ommend  early  PCI  to  patients  with  diabetes
mellitus or the metabolic syndrome who have sta-
ble CAD.
In the Bypass Angioplasty Revascularization
Investigation 2 Diabetes (BARI 2D ) trial, 2,368
patients with diabetes mellitus and CAD were ran-
domized to undergo either prompt coronary revas-
cularization with intensive medical therapy or inten-
sive medical therapy alone and to undergo either
insulin-sensitization or insulin-provision therapy
[16]. Randomization was stratified according to the
choice of PCI or coronary artery bypass grafting
(CABG). At 5-year follow-up, survival was 88.3% for
the coronary revascularization group and 87.8% for
the medical therapy alone group (p not significant)
and 88.2% for the insulin-sensitization group and
87.9% for the insulin-provision group (p not signif-
icant). The incidence of freedom from major car-
diovascular events was also not significantly dif-
ferent between the coronary revascularization and
medical therapy alone groups and between the
insulin-sensitization and insulin provision groups.
In the PCI stratum, the primary endpoints of death
and of death or major cardiovascular events were
similar in the PCI and medical therapy alone groups.
However, in the CABG stratum, the incidence of
death or myocardial infarction or stroke was 22.4%
in the CABG group vs. 30.5% in the medical thera-
py alone group (p = 0.01) [16].
In the BARI 2 D trial, 1,191 patients were ran-
domized to optimal medical therapy alone and 1,173
patients to coronary revascularization with 796
patients preselected for PCI and 377 patients to
CABG [17]. Compared with the medical therapy
group alone, at 3-year follow-up, the coronary revas-
cularization group had a lower incidence of wors-
ening angina pectoris (8% vs. 13%, p < 0.001), a low-
er incidence of new angina pectoris (37% vs. 51%,
p = 0.001), a lower incidence of subsequent coro-
nary revascularization (18% vs. 33%, p < 0.001), and
a higher incidence of angina-free status (66% vs.
58%, p = 0.003). The CABG patients were at high-
er risk than the PCI patients and had the greatest
benefits from coronary revascularization. The symp-
tomatic benefits were observed particularly for
high-risk patients. 
These data favor optimal medical therapy alone
in patients with diabetes mellitus and stable CAD.
However, if disabling angina pectoris despite opti-
mal medical therapy occurs, I would recommend
coronary revascularization. In high-risk patients,
I would recommend CABG over PCI at this time. At
10.4-year follow-up of diabetics with CAD in the
BARI trial, the CABG group had a survival rate of
57.8% vs. 45.5% for the PCI group (p = 0.025) and
a subsequent coronary revascularization incidence
of 20.3% for the CABG group vs. 76.8% for the PCI
group (p < 0.001) [18].
On the basis of the available data, I would treat
patients with diabetes mellitus and ST-segment ele-
vation myocardial infarction [19] or unstable angi-
na/non-ST-segment elevation myocardial infarction
[20] with coronary revascularization with the choice
of PCI or CABG depending on the coronary angio-
graphic findings. The blood sugar in these patients
should have a target goal between 140-180 mg/dl.
Diabetics who have received stents should be treat-
ed with dual antiplatelet therapy for at least 1 year
after PCI and preferably longer. 
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